Life
Merck’s Experimental HIV Prevention Pill Could Cost Less Than $5 a Year
Strategic angle: Researchers advocate for urgent licensing of generic production to enhance accessibility.
editorial-staff
1 min read
Updated 4 days ago
Merck's new HIV prevention pill has been assessed for its potential affordability, with estimates suggesting a production cost of less than $5 per year.
Research advocates emphasize the need for Merck to license generic production urgently, which could facilitate broader access to this crucial medication.
The implications of such a low-cost option could significantly impact at-risk populations, enhancing public health outcomes through improved accessibility.